Sulfathiazole is an organosulfur compound used as a short-acting sulfa drug. Formerly, it was a common oral and topical antimicrobial, until less toxic alternatives were discovered. Sulfathiazole exists in various forms. The imine tautomer is dominant in the solid state and in aprotic solvents, and the compound displays amine-imine tautomerism that affects its spectroscopic signature and crystallization behavior. Chemically it is a sulfonamide bearing a thiazole ring, formula C9H9N3O2S and molar mass about 255.25 g mol 1. It is sparingly soluble in water, more soluble in alcohols and some organic solvents, and has an approximate melting point near 204 degrees C. As a representative sulfonamide it exerts bacteriostatic action by competing with para aminobenzoic acid at dihydropteroate synthase in folate biosynthesis. Typical analytical characterization includes UV, IR, NMR and HPLC profiles and control of tautomeric form and polymorphs is important for consistent formulation and stability.
Parent: Sulfathiazole
Parent: Sulfathiazole
Commercial and pharmaceutical grade sulfathiazole is routinely released to specification with tight control of assay, moisture, heavy metals and related substances. Typical quality limits applied by manufacturers are assay about 98.0 to 102.0 percent, water content (loss on drying) typically <= 0.5 to 1.0 percent, and heavy metals controlled to low ppm levels (for example <= 20 ppm) depending on customer requirements. Related substances are monitored by HPLC or LC MS and are commonly specified so that any individual unspecified impurity is kept below about 0.1 to 0.5 percent and total impurities are maintained below about 1.0 to 2.0 percent, with tighter limits applied for critical impurities. Common related compounds and degradation products that are specifically screened include N4 acetylsulfathiazole, sulfathiazole N oxide, sulfanilamide arising from ring cleavage, and other desulfonylated or hydrolytic products. Residual solvents and microbial limits are controlled as applicable and stability studies guide storage conditions to minimize impurity formation.
Sulfathiazole was used as an oral and topical antibacterial agent active against a range of Gram positive and some Gram negative organisms by inhibiting folate synthesis. Today its systemic use has been largely discontinued in human medicine because safer, more effective sulfonamides and other antibiotic classes are available, though it may still appear in historical formulations, certain topical preparations, or limited veterinary applications.
There is no single widely recorded event officially termed the sulfathiazole disaster. Public concern and regulatory action around sulfonamide medicines arose historically after toxic incidents with related preparations, most famously the 1937 elixir sulfanilamide tragedy involving diethylene glycol as a solvent. Sulfathiazole itself produced adverse reactions in some patients, including hypersensitivity and blood dyscrasias, which contributed to its decline in use, but it is not associated with a unique large scale disaster distinct from broader early sulfa drug safety issues.
No, Sulfathiazole is not commonly used in contemporary human medicine because safer and better tolerated antibiotics have replaced it. It can still be encountered in legacy formulations, some topical or veterinary contexts, and in reference or research settings. Use where it remains employed is governed by local regulations, current safety data and availability of alternatives.
